



Disclaimer



This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

1st Quarter 2011 – Bayer Off To A Successful Start



- **Strong business expansion, all subgroups contributing**, sales up 13% (10%) to €9.4bn, adj. EBITDA up 22% at €2.2bn, Core EPS up 28% to €1.45
- **Reported earnings impacted by high special charges**, €442m special charges due to restructuring and litigation, reported EPS at €0.83 up 9%
- **Strong cash generation**, net cash flow up 9% to €801m, oFCF up 12% to €563m, net debt lowered by €0.8bn to €7.1bn (q-o-q)
- **Full-year group guidance for 2011 raised on expected improvement at CropScience**


Q1 2011 Investor Conference Call • Marijn Dekkers • Page 3

1st Quarter 2011 – Off To A Successful Start



Sales


in € million
% portfolio & currency adj.



+10%

EBITDA

pre-special items
in € million



+22%

Core EPS


in €



+28%

Net Cash Flow

in € million



+9%

Q1 2011 Investor Conference Call • Marijn Dekkers • Page 4

1st Quarter 2011 – Reported Earnings Development



In € million

	Q1 2010	Q1 2011	Δ%
EBIT	1,104	1,148	+4
Non-operating result	-244	-213	+13
Pre-tax income	860	935	+9
Net income	631	684	+8
Earnings per share	€0.76	€0.83	+9


Q1 2011 Investor Conference Call • Marijn Dekkers • Page 5

1st Quarter 2011 – Strong Growth In All Regions Led By Emerging Markets




In € million, Δ% yoy Fx adjusted

Q1 2011 Group sales by region



Emerging Economies



Q1 2011 Investor Conference Call • Marijn Dekkers • Page 6

¹ Emerging economies include: Latin America, Asia w/o Japan, Australia, New Zealand, Africa and Middle East incl. Turkey, Eastern Europe
² Others = Japan, Australia, New Zealand, Canada
³ Emerging Asia = Asia minus Japan, Australia, New Zealand

1st Quarter 2011 – Cash Flow And Net Debt Development



Q1 2011 Cash Flow

In € million

	GCF	NCF cont.	Investments	oFCF
	1,309	801	238	563
Δ % y-o-y	+11%	+9%	+3%	+12%

Net Debt Development

In € billion



Q1 2011 Investor Conference Call • Marijn Dekkers • Page 7

1st Quarter 2011 – All Segments Contributed To The Business Expansion



In € million, () = Fx & portfolio adjusted

	Sales			adj. EBITDA		
	2010	2011	Δ% (adj.)	2010	2011	Δ%
HealthCare	3,869	4,166	+8 (+4)	1,023	1,140	+11
Pharma	2,531	2,649	+5 (+1)	759	803	+6
Consumer Health	1,338	1,517	+13 (+10)	264	337	+28
CropScience	1,952	2,257	+16 (+14)	531	745	+40
Crop Protection	1,476	1,676	+14 (+12)	352	510	+45
ES/BS¹	476	581	+22 (+18)	179	235	+31
MaterialScience	2,216	2,686	+21 (+19)	278	345	+24

¹ Environmental Science/BioScience

Q1 2011 Investor Conference Call • Marijn Dekkers • Page 8

Group Outlook Raised On Expected Improvement At CropScience



Sales Δ Fx and portfolio adjusted, EBITDA pre-special items

	2010	Δ		2011E (previous guidance)	2011E (revised guidance)
Sales (Fx & portf. adjusted)	€35.1bn	+8%		4-6% to €35-36bn	5-7% to €36-37bn
adj. EBITDA	€7.1bn	+10%		improve toward €7.5bn	> €7.5bn
Core EPS	€4.19	+15%		≈10%	≈15%

Outlook depends on specific planning assumptions as detailed in the Q1 Quarterly Report

Q1 2011 Investor Conference Call • Marijn Dekkers • Page 9

2011 Revised Guidance By Subgroup



Outlook based on Fx and portfolio adj. sales and EBITDA pre-special items

HealthCare		Unchanged: Low- to mid-single digit increase of sales and small increase of adj. EBITDA
Pharma		Unchanged: Low- to mid-single digit increase of sales and improvement of adj. EBITDA-margin
Consumer Health		Unchanged: Mid-single digit growth of sales and adj. EBITDA
CropScience		Raised: High- (previously: mid-) single-digit percentage higher sales and growth of adj. EBITDA by approx. 20% (previously: at a higher rate than sales)
MaterialScience		Updated to reflect raw material cost induced price increases High- (so far: mid-) single digit percentage increase of sales and growth of adj. EBITDA at a higher rate than sales. Q2'11: Higher sales and improved adj. EBITDA versus Q1'11

Q1 2011 Investor Conference Call • Marijn Dekkers • Page 10

Outlook depends on specific planning assumptions as detailed in the Q1 Quarterly Report



Science For A Better Life



Investor Conference Call
Q1 2011 Results

Marijn Dekkers, CEO | April 28, 2011